Pershing Square Sohn Cancer Research Alliance

The Pershing Square Sohn Cancer Research Alliance is dedicated to playing a catalytic role in accelerating cures for cancer by enabling the pursuit of the most innovative and advanced cancer research and by facilitating collaborations between science and business.

Early-Stage Funding for Cancer Research

The Prize for young investigators provides early-stage funding opportunities to New York scientists with innovative ideas in cancer research. The program surrounding the Prize is a catalyst in bridging the gap between the academic scientific community and the business community.


2022 Prize Winners


October 3, 2022
The Pershing Square Sohn Cancer Research Alliance Is Now Accepting Applications for its 2023 Prize for Radically Innovative, Early-Career Cancer Researchers

BUSINESS WIRE / THE PERSHING SQUARE FOUNDATION – The Pershing Square Sohn Cancer Research Alliance (PSSCRA) today announced the opening of applications for the 2023 Pershing Square Sohn Prize for Young Investigators in Cancer Research. The prize of $200,000 per year for three years is awarded annually to at least six New York City area-based scientists. The Prize empowers researchers to pursue novel, high-risk/high-reward cancer research at a stage when traditional funding is lacking.

“AI-powered biotech has enabled the deployment of the COVID vaccine in record time, inspiring a paradigm shift in human health. With much investigation into the molecular basis for cancer underway, in combination with innovations in DNA sequencing, artificial intelligence, machine learning, and precision oncology, researchers are well-positioned to diagnose, treat, and cure cancer by considering a single patient as the entire trial,” said Pershing Square Foundation Trustee Neri Oxman. “Along with these promising new horizons in cancer technologies, we are excited to welcome a new generation of scientists eager to make an impact, one patient at a time, in record time.”



June 8, 2022 

On Wednesday, June 8 the Pershing Square Sohn Cancer Research Alliance held its 2022 Prize Dinner at Bar65 at the Rainbow Room in New York, awarding its 2022 Pershing Square Sohn Prize for Young Investigators in Cancer Research to seven early-career pioneers in cancer research in the greater New York City area.

The evening began with cocktails on the terrace, followed by a seated dinner. To start the dinner, Olivia Tournay Flatto, PhD, President of The Pershing Square Foundation and Co-founder and Executive Director of the Pershing Square Sohn Cancer Research Alliance gave introductory remarks. The special guest speaker for the evening was Scientific Review Council Member Ali Brivanlou, PhD, Robert & Harriet Heilbrunn Professor at The Rockefeller University, who gave a fascinating presentation on his work with embryonic stem cells, the innovations in this space, and the ethical considerations, followed by a provocative and stimulating Q&A session. After the entrée, Scientific Review Council Member Dave Tuveson, MD, PhD, Roy J. Zuckerberg Professor of Cancer Research at Cold Spring Harbor Laboratory, introduced the seven Pershing Square Sohn Prize winners with a special video and welcomed The Pershing Square Foundation Co-Trustees William Ackman and Neri Oxman to lead the award ceremony.  Prize Advisory Board 2022 Chair Jim Rothman, PhD, Sterling Professor of Cell Biology and Professor of Chemistry at Yale School of Medicine, gave concluding remarks.


“The Pershing Square Foundation is proud to support scientific leaders in the fight against cancer.”

Bill Ackman, Co-Founder. The Pershing Square Foundation